V. Attignon

发表

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Nicolas Servant, Anne Vincent-Salomon, Xavier Paoletti, 2015, The Lancet. Oncology.

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

S. Boyault, J. Iovanna, N. Dusetti, 2021, Cancers.

Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports

C. Carrie, V. Attignon, D. Pissaloux, 2018, Journal of Medical Case Reports.

Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel

A. Viari, P. Saintigny, O. Trédan, 2022, medRxiv.

Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer.

S. Boyault, S. Lantuejoul, C. Caux, 2022, European journal of cancer.

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.

S. Lantuejoul, C. Caux, P. Saintigny, 2022, European Journal of Cancer.

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)

F. Guyon, I. Treilleux, I. Ray-Coquard, 2020, Cancers.

Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers

J. Blay, D. Maucort-Boulch, E. Pasquier, 2022, bioRxiv.

Tumor Molecular Profiling: Pediatric Results of the ProfiLER Study.

J. Blay, D. Frappaz, P. Saintigny, 2020, JCO precision oncology.

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

J. Honnorat, I. Treilleux, I. Ray-Coquard, 2018, Acta Neuropathologica.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Results of the SHIVA trial.

S. Boyault, A. Vincent-Salomon, I. Bièche, 2015 .

Genomics to select treatment for patients with metastatic breast cancer

P. Gestraud, S. Boyault, I. Bièche, 2022, Nature.

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial

J. Blay, A. Viari, I. Treilleux, 2022, Journal of personalized medicine.

Primary Melanoma of the Leptomeninges with BAP1 Expression‐Loss in the Setting of a Nevus of Ota: A Clinical, Morphological and Genetic Study of 2 Cases

V. Rigau, F. Labrousse, V. Attignon, 2016, Brain pathology.

Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol

N. Magné, J. Blay, I. Ray-Coquard, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Somatic MMR Gene Mutations as a Cause for MSI‐H Sebaceous Neoplasms in Muir–Torre Syndrome‐Like Patients

J. Saurin, C. Audoynaud, Qing Wang, 2015, Human mutation.

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.

P. Saintigny, M. Kamal, J. Fayette, 2021, Oral oncology.

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial

J. Blay, O. Trédan, H. Vanacker, 2020, Translational oncology.

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.

J. Blay, A. Viari, I. Ray-Coquard, 2019, European journal of cancer.

Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial

J. Blay, F. Ducray, S. Lantuejoul, 2021, Medical Oncology.

Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol

N. Magné, J. Blay, O. Trédan, 2021, Head & neck.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

J. Blay, S. Boyault, S. Lantuejoul, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfiLER study.

J. Blay, A. Viari, O. Trédan, 2017 .

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study

I. Treilleux, I. Ray-Coquard, C. Caux, 2023, Breast cancer.

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.

I. Ray-Coquard, O. Trédan, N. Chopin, 2017, Annals of Oncology.

Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors

P. Varlet, O. Delattre, D. Frappaz, 2023, Cancers.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

J. Blay, S. Boyault, S. Lantuejoul, 2019 .

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors

S. Lantuejoul, C. Caux, P. Saintigny, 2022, Data in brief.

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

J. Blay, F. Bertucci, S. Boyault, 2023, Cancers.

Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.

J. Blay, D. Frappaz, P. Biron, 2014 .

Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

I. Bièche, I. Soubeyran, F. André, 2017 .

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program

J. Blay, S. Boyault, I. Ray-Coquard, 2021, Translational oncology.

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas

J. Blay, E. Pasquier, Laura Broutier, 2024, bioRxiv.

MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case

R. Schiappa, Qing Wang, M. Joly, 2019, Familial Cancer.

Different Genetic Signatures of Small‐Cell Lung Cancer Characterize Anti‐GABABR and Anti‐Hu Paraneoplastic Neurological Syndromes

A. Viari, M. Brevet, V. Attignon, 2023, Annals of neurology.

p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane

F. Dalenc, P. Cottu, T. Bachelot, 2024, British journal of cancer.

IDHwt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.

Michelle S. Scott, Danny Bergeron, F. Ducray, 2023, Neuro-oncology.

Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers

E. Pasquier, Clara Savary, Laura Broutier, 2023, Cell reports. Medicine.